Tanvex BioPharma, Inc. (TPE:6541)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
56.50
-0.30 (-0.53%)
At close: Dec 5, 2025

Tanvex BioPharma Balance Sheet

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Cash & Equivalents
1,393376.96380.75786.232,2232,069
Upgrade
Cash & Short-Term Investments
1,393376.96380.75786.232,2232,069
Upgrade
Cash Growth
87.72%-1.00%-51.57%-64.63%7.46%-14.78%
Upgrade
Accounts Receivable
119.030.079.40.332.52-
Upgrade
Other Receivables
95.1731.5827.4327.3625.3125.57
Upgrade
Receivables
214.2131.6536.8327.6927.8425.57
Upgrade
Inventory
410.27217.84108.29170.8490.3350.08
Upgrade
Prepaid Expenses
39.5649.1878.3558.9560.85119.25
Upgrade
Total Current Assets
2,062675.62604.211,0442,4022,264
Upgrade
Property, Plant & Equipment
2,3591,8271,9282,1512,1141,906
Upgrade
Other Intangible Assets
496.297.073.3812.0710.1711.96
Upgrade
Other Long-Term Assets
421.31225.3227.67213.47187.58190.98
Upgrade
Total Assets
8,1752,7352,7633,4204,7144,373
Upgrade
Accounts Payable
42.89-----
Upgrade
Accrued Expenses
127.22134.27-115.93137.49210.99
Upgrade
Current Portion of Long-Term Debt
-----54.77
Upgrade
Current Portion of Leases
173.09160.01163.45124.6588.7565.74
Upgrade
Current Income Taxes Payable
26.89-----
Upgrade
Current Unearned Revenue
98.5911.116.9128.07--
Upgrade
Other Current Liabilities
225.742.75193.3834.6322.2821.6
Upgrade
Total Current Liabilities
694.38348.14363.73303.29248.51353.1
Upgrade
Long-Term Debt
-----35.53
Upgrade
Long-Term Leases
1,3731,4881,5681,7151,6701,363
Upgrade
Long-Term Unearned Revenue
104.025.4710.23---
Upgrade
Other Long-Term Liabilities
1.72--10.47--
Upgrade
Total Liabilities
2,1731,8421,9422,0281,9191,752
Upgrade
Common Stock
2,6481,6411,3403,5273,5253,116
Upgrade
Additional Paid-In Capital
18,89813,56712,43111,06110,9889,653
Upgrade
Retained Earnings
-15,216-14,136-12,755-12,969-11,327-9,784
Upgrade
Comprehensive Income & Other
-328.32-177.94-194.17-227.09-390.12-364.04
Upgrade
Shareholders' Equity
6,002893.31821.111,3912,7952,621
Upgrade
Total Liabilities & Equity
8,1752,7352,7633,4204,7144,373
Upgrade
Total Debt
1,5461,6481,7321,8391,7591,519
Upgrade
Net Cash (Debt)
-153.42-1,271-1,351-1,053463.95549.19
Upgrade
Net Cash Growth
-----15.52%-73.66%
Upgrade
Net Cash Per Share
-0.70-8.19-10.48-8.954.276.14
Upgrade
Filing Date Shares Outstanding
264.82164.07133.96117.64117.57103.95
Upgrade
Total Common Shares Outstanding
264.82164.07133.96117.64117.57103.95
Upgrade
Working Capital
1,367327.48240.48740.432,1531,910
Upgrade
Book Value Per Share
22.665.446.1311.8323.7725.21
Upgrade
Tangible Book Value
2,674886.24817.731,3792,7852,609
Upgrade
Tangible Book Value Per Share
10.105.406.1011.7323.6825.10
Upgrade
Machinery
1,3161,089982.54975.18889.53884.87
Upgrade
Construction In Progress
371.9544.3483.7172.8253.848.78
Upgrade
Leasehold Improvements
573.26509.94415.69388.62318.95322.42
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.